163 related articles for article (PubMed ID: 38482676)
1. Pleomorphic/solid lobular carcinoma of male breast with PALB2 germline mutation: case report and literature review.
Rogges E; Corati T; Amato M; Campagna D; Farro J; De Toffol S; Fortunato L; Costarelli L
Pathologica; 2024 Feb; 116(1):62-68. PubMed ID: 38482676
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
[TBL] [Abstract][Full Text] [Related]
3. BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case.
Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Cioffi M; Molinari AM
Eur J Med Genet; 2020 Jun; 63(6):103883. PubMed ID: 32058061
[TBL] [Abstract][Full Text] [Related]
4. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Pathogenic Germline Variants in
Petridis C; Arora I; Shah V; Moss CL; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Cancer Epidemiol Biomarkers Prev; 2019 Jul; 28(7):1162-1168. PubMed ID: 31263054
[TBL] [Abstract][Full Text] [Related]
7. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
8. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
9. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
Rizzolo P; Zelli V; Silvestri V; Valentini V; Zanna I; Bianchi S; Masala G; Spinelli AM; Tibiletti MG; Russo A; Varesco L; Giannini G; Capalbo C; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Peterlongo P; Radice P; Palli D; Ottini L
Int J Cancer; 2019 Jul; 145(2):390-400. PubMed ID: 30613976
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
12. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.
Ding YC; Steele L; Kuan CJ; Greilac S; Neuhausen SL
Breast Cancer Res Treat; 2011 Apr; 126(3):771-8. PubMed ID: 20927582
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
[TBL] [Abstract][Full Text] [Related]
15. Genetic predisposition to male breast cancer in Poland.
Szwiec M; Tomiczek-Szwiec J; Kluźniak W; Wokołorczyk D; Osowiecka K; Sibilski R; Wachowiak M; Gronwald J; Gronwald H; Lubiński J; Cybulski C; Narod SA; Huzarski T
BMC Cancer; 2021 Aug; 21(1):975. PubMed ID: 34461861
[TBL] [Abstract][Full Text] [Related]
16. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.
Ottini L; Rizzolo P; Zanna I; Falchetti M; Masala G; Ceccarelli K; Vezzosi V; Gulino A; Giannini G; Bianchi S; Sera F; Palli D
Breast Cancer Res Treat; 2009 Aug; 116(3):577-86. PubMed ID: 18819001
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
20. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
